News und Analysen

Obesity is a global health crisis and is a direct or indirect cause of various health conditions. The emergence of GLP-1 agonists over the past several years has ignited one of the most significant

Healthcare stocks are not known for healthy dividends. Great for growth, yes, but often so-so for dividend yields. The average medical large-cap stock's dividend yield was 1.67% at the end of 2025

The story of Nvidia's (NASDAQ: NVDA) ascent to become the most valuable stock in the world has dominated headlines for the past several years. But what many investors may not realize is that the

Over the past five years, Axsome Therapeutics (NASDAQ: AXSM) has been on fire. The company has crushed the market in this period on the back of solid clinical and regulatory progress. At this point

Pfizer (NYSE: PFE) stock gave up 3.3% through 10:50 a.m. ET Tuesday despite delivering an earnings beat this morning.

Analysts forecast the pharmaceuticals giant would earn $0.57 per share on $16.8

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other AI stocks. To learn more, check out the short video, consider subscribing, and click the special

Hindsight is perfect. It's easy now to look back and think that artificial intelligence chip pioneer Nvidia (NASDAQ: NVDA) was always destined for greatness, given that it now has the largest market

Shares of Abbott Laboratories (NYSE: ABT) recently plunged after the company announced its fourth-quarter results. Over the trailing 12 months, the stock is down 16%. Some might choose to stay away

Pfizer (NYSE: PFE) is one of the world's largest pharmaceutical companies. It has a long history of innovation and success. Add in a lofty 6.6% dividend yield, and dividend investors are likely to

In some ways, AbbVie (NYSE: ABBV) isn't the same company it was five years ago. Sure, it's still in the biopharmaceuticals business. However, AbbVie has a new CEO. More importantly, it no longer

Shares of AT&T (NYSE: T) jumped more than 10% this past week, according to data from S&P Global Market Intelligence.

The wireless carrier delivered an impressive quarterly financial report and

Last month, millions of people made New Year's resolutions. Many of them have likely already come to a halt. But the experiment I started on Jan. 1 is still going strong, and as the new Voyager

Pfizer (NYSE: PFE) got a huge boost during the coronavirus pandemic thanks to its COVID-19 vaccine. Since that point, however, investors have soured on the stock, which has lost more than half its

Over the past decade, AbbVie (NYSE: ABBV) and Mastercard (NYSE: MA) have produced strong market returns. Their performance is even better once we account for dividends reinvested. That is one of the

John Walter Hanna Jr., President and CEO of CareDx (NASDAQ:CDNA), directly sold 19,480 shares in multiple open-market transactions on Jan. 21 and Jan. 22, 2026, for a total value of approximately

Over the last three years, OpenAI and Anthropic have evolved from speculative artificial intelligence (AI) laboratories into full-blown infrastructure behemoths. Between the two companies, trillions

In the volatile biotech industry, companies can see their shares soar over relatively short periods on strong clinical progress for exciting pipeline candidates.

That's precisely what could happen

Marc Stapley, a director at Glaukos Corporation (NYSE:GKOS), executed a direct sale of 15,000 shares for a transaction value of approximately $1.9 million on Jan. 22, 2026, following the exercise of

In a move that may surprise nobody, artificial intelligence (AI) hyperscalers are planning to double down on their infrastructure spend this year. According to FactSet Research, big tech is forecast

Investors remain extremely upbeat about the outlook for artificial intelligence (AI) stocks, despite fears of an AI bubble. The likely reason is the expectation that these complex computer programs

AbbVie (NYSE: ABBV) is one of the largest pharmaceutical companies in the world. Though its portfolio spans many therapeutic areas, it is particularly well known for its work in immunology, a field

John Hanna, President and CEO of CareDx (NASDAQ:CDNA), directly sold 19,480 shares in multiple open-market transactions on Jan. 21, 2026 and Jan. 22, 2026, with an aggregate transaction value of

David Novack, President & COO of Dynavax Technologies Corporation (NASDAQ:DVAX), exercised 114,000 stock options and immediately sold the resulting shares for a transaction value of approximately

Some investors are skeptical of companies with high dividend yields, since it sometimes signals that the dividend may be unsustainable. However, plenty of high-yield dividend stocks look solid

When most people think of artificial intelligence (AI) winners, names like Nvidia or Advanced Micro Devices might come to mind. These are chip designers that are powering key AI tasks like the